Alliances
Bristol-Myers Squibb announced that it has expanded its relationship with Flatiron Health, extending a three-year collaboration agreement.
As Biogen turns 40 years old, some biotech insiders and analysts seem to be concerned that the Boston-based pharmaceutical company has too many eggs in one developmental basket.
Chinese investment firms 3SBio and Sequoia China joined a team of other investors to bankroll California-based Refuge Biotechnologies, Inc.’s $25 million funding round to support its gene therapy treatments using CRISPR technology.
Sanofi and Regeneron made a deal with pharmacy benefits manager Express Scripts for their Praluent, making it the exclusive PCSK9 inhibitor on their national formulary, essentially locking Amgen’s Repatha out of that market segment.
The two companies will use Verity’s Immunoscape platform to profile the molecular characteristics of inflammatory diseases.
Merck appears to be on the way to securing an additional approval for Keytruda, its blockbuster checkpoint inhibitor. The company is seeking new regulatory approval for Keytruda, an anti-PD-1 therapy, in combination with Eli Lilly’s Alimta and platinum chemotherapy as a first-line lung cancer treatment.
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
Humira, the world’s best-selling drug, keeps on churning out positive sales results for AbbVie, despite looming challenges.
Shares of Adocia are up nearly 30 percent this morning after the company announced it granted exclusive development and commercialization rights of its insulin products to Tonghua Dongbao Pharmaceuticals.
China continues to be a hotbed of investment for U.S. pharmaceutical and biotech companies. Last week BioSpace reported that China expects to see exponential industry growth by 2022 and today Eli Lilly and Company added to that growth through a partnership with China’s National Center for Cardiovascular Diseases.
PRESS RELEASES